Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of childbearing age and is chracterized by unpredictable flares and remissions , disease variety varied from mild episode disorder to arpidly progressive life -threatening illness.. LN is diagnosed by either the presence of proteinuria \>0.5g/day. active urinary sediment , or an unexplained rise in serum creatinine there fore , identifying new invasive biomarkers of LN severity and outcome is mandatory, Renal Arterial resistive index ( RRI) is anon invasive biomarker that has been studied as apotential indicator of disease activity in LN patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged ≥18 years. - SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. - Patients cooperative and can answer questions. - Patients who are able and willing to give written willing to sign a consent form. Who Should NOT Join This Trial: - • Individuals with other autoimmune conditions (where your immune system attacks your own body)s. - Diabetes. - Hypertension. - Heart failure. - Hepatic diseases. - Chronic renal failure. - Renal artery stenosis. - Renal vein thrombosis. - Intrarenal arteriovenous fistula. - Obstructive nephropathy. - Urinary tract obstruction that could affect RI of intra renal arteries. - Un cooperative patients. - Patients not able and willing to give written willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent. Exclusion Criteria: * • Individuals with other autoimmune diseases. * Diabetes. * Hypertension. * Heart failure. * Hepatic diseases. * Chronic renal failure. * Renal artery stenosis. * Renal vein thrombosis. * Intrarenal arteriovenous fistula. * Obstructive nephropathy. * Urinary tract obstruction that could affect RI of intra renal arteries. * Un cooperative patients. * Patients not able and willing to give written informed consent.

Treatments Being Tested

DIAGNOSTIC_TEST

renal doppler

doppler srudy on renal arteries bilaterally , and detection of RI of renal artery

Locations (1)

Sohag university Hospital
Sohag, Egypt